Phase 3, multicentre, randomised, double-blind, placebo-controlled, parallel-group study of ustekinumab in Japanese patients with active polymyositis and dermatomyositis who have not adequately responded to one or more standard-of-care treatments.
Kimito KawahataTomonori IshiiTakahisa GonoYumi TsuchiyaHiroki OhashiKatsunori YoshizawaRichuan ZhengMaori AyabeKazuko NishikawaPublished in: RMD open (2023)
NCT03981744.
Keyphrases
- double blind
- placebo controlled
- interstitial lung disease
- clinical trial
- systemic sclerosis
- study protocol
- healthcare
- phase iii
- phase ii
- palliative care
- rheumatoid arthritis
- idiopathic pulmonary fibrosis
- phase ii study
- quality improvement
- pain management
- disease activity
- affordable care act
- cross sectional
- rectal cancer